C
ABBV icon

CEDRUS’s AbbVie ABBV Stock Holding History

CEDRUS’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$295K Sell
1,495
-475
-24% -$88.7K 0.11% 142
2024
Q2 		$338K Buy
1,970
+13
+0.7% +$2.15K 0.17% 107
2024
Q1 		$356K Sell
1,957
-408
-17% -$70.3K 0.19% 99
2023
Q4 		$367K Sell
2,365
-326
-12% -$47.5K 0.23% 97
2023
Q3 		$401K Buy
2,691
+236
+10% +$34.6K 0.29% 74
2023
Q2 		$331K Buy
2,455
+25
+1% +$3.67K 0.23% 100
2023
Q1 		$387K Buy
+2,430
New +$372K 0.27% 80

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

CEDRUS's ABBV Position: Q3 2024 in Review

CEDRUS reduced its AbbVie (ABBV) stake by 24% in Q3 2024, selling an estimated $88.7K and leaving 1,495 shares worth $295K. The position accounts for 0.11% of the portfolio, ranked #142.

CEDRUS first reported a position in ABBV in Q1 2023 and has held it in 7 quarters since. The position peaked at $401K in Q3 2023. 3,500 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • CEDRUS held 1,495 shares of AbbVie worth $295K as of Q3 2024.
  • CEDRUS sold 475 AbbVie shares in Q3 2024, an estimated $88.7K.
  • AbbVie made up 0.11% of CEDRUS's portfolio in Q3 2024, its #142 holding.
  • CEDRUS first reported a position in AbbVie in Q1 2023 and has held it in 7 quarters since.
  • CEDRUS's AbbVie position peaked at $401K in Q3 2023.
  • 3,500 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on CEDRUS's 13F filing for Q3 2024, filed 18 Oct 2024.